

MAR 14 2003

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: March 14, 2003

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/081,185
Filing Date 02/25/2002
First Named Inventor Thomas Dag Horn et al.
Group Art Unit 1642
Examiner Name Unassigned
Attorney Docket Number 023533-0144

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁵ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|--|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|-----------------------|--|----------------|
| GN | A1 | JOHNSON ET AL., "Intralesional Injection of Mumps or <i>Candida</i> Skin Test Antigens; A Novel Immunotherapy for Warts," <i>Arch. Dermatol.</i> (Apr. 2001), Vol. 137, pp. 451-455. | |
| | A2 | PHILLIPS ET AL., "Treatment of Warts with <i>Candida</i> Antigen Injection," <i>Archives of Dermatology</i> (October 2001), full paper, 7 pages. | |
| | A3 | PHILLIPS ET AL., "Treatment of Warts with <i>Candida</i> Antigen Injection," <i>Arch. Dermatol.</i> (October 2000), Vol. 136, pp. 1274-1275, Vignette. | |
| | A4 | SIGNORE, Letter commenting on "Candida Immunotherapy of Warts," <i>Arch. Dermatol.</i> (Sept. 2001), Vol. 137, pp. 1250-1251. | |
| | A5 | HARADA, "Clinical application of fungus extracts and their culture filtrates in the treatment of skin diseases: <i>Candida</i> vaccine in the treatment of warts," <i>The Japanese Journal of Dermatology (Nippon Hifuka Gakkai Zasshi)</i> (1979), Vol. 89, No. 6, pp. 397-402. | |
| | A6 | MCCONAHY, "Common Warts: Immunity as a Result of Therapy," <i>CUTIS</i> (February 1976), Vol. 17, pp. 301-304. | |
| | A7 | GREENSHER, "The Treatment of Warts with Mumps Skin Test Antigen," <i>Society of Teachers of Family Medicine</i> , 9 pages. | |
| | A8 | GREENSHER, "Treatment of Laryngeal Papillomas with Mumps Skin Test Antigen," <i>The Lancet</i> (October 25, 1980), pp. 920-921. | |
| | A9 | NAYLOR ET AL., "Contact immunotherapy of resistant warts," <i>Journal of the American Academy of Dermatology</i> (Oct. 1988), Vol., 19, No. 4, pp. 679-683, Abstract. | |

Examiner Signature

Ray B. Nickel

Date Considered

7/13/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: March 14, 2003

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

| | |
|------------------------|------------------------|
| Applicati n Numb r | 10/081,185 |
| Filing Date | 02/25/2002 |
| First Named Inv ntor | Thomas Dag Horn et al. |
| Group Art Unit | 1642 |
| Examiner Name | Unassigned |
| Attorney Docket Number | 023533-0144 |


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|--------------------|-----------------------|--|----------------|
| GN | A10 | PARSAD ET AL., "Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children," <i>Pediatric Dermatology</i> (Jul.-Aug. 2001), Vol. 18, No. 4, pp. 349-352, Abstract. | |
| | A11 | AVENTIS PASTEUR, "Mumps Skin Test Antigen USP," Product Information Brochure as of February 1997, 2 pages. | |
| | A12 | CANDIN®, Package Insert Text, 8 pages. | |

RECEIVED

MAR 20 2003

TECH CENTER 1600/2900

Examiner
Signature

Date
Considered

7/13/04


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

| | | | | | | | |
|--|--|-----------------------------|--|---------------------|--|----------------|--|
| Form PTO-1449 | | U.S. DEPARTMENT OF COMMERCE | | ATTY. DOCKET NO. | | SERIAL NO. | |
| (MODIFIED) | | PATENT AND TRADEMARK OFFICE | | 023533/0144 | | unassigned | |
| INFORMATION DISCLOSURE CITATION | | | | APPLICANT | | | |
| | | | | Thomas HORN, et al. | | | |
| Date Submitted to PTO: February 25, 2002 | | | | FILING DATE | | GROUP ART UNIT | |
| | | | | February 25, 2002 | | 1642 | |

10/08/05
 10971 U.S. PTO
 02/25/02

| U.S. PATENT DOCUMENTS | | | | | | | | |
|---|---|--------------------|--|----------------|-----------------|---------------|----------------------------------|--|
| EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE | |
| CW | A1 | 5,662,903 | 09/02/1997 | BOYER et al. | 1 | 1 | | |
| | A2 | 6,123,948 | 09/26/2000 | Whittle et al. | 1 | 1 | | |
| OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | |
| CW | A3 | AMER et al. | "Therapeutic evaluation for intralesional injection of bleomycin sulfate in 143 resistant warts," <i>J. Amer. Acad. Dermatol.</i> , 18(15):1313-6 (1988) | | | | | |
| | A4 | BAKER et al. | "Therapeutic Approaches to Papillomavirus Infections," <i>Infectious Diseases in Dermatology</i> , 15(2):331-340 (1997) | | | | | |
| | A5 | BOLIN | <i>Equine Disease Quarterly</i> , Vol. 7, No. 3 (April 1999) | | | | | |
| | A6 | BRODELL et al. | "The Treatment of Palmar and Plantar Warts Using Natural Alpha Interferon and a Needleless Injector," <i>Dermatol Surg.</i> , 21:213-218 (1995) *Elsevier Science, Inc. | | | | | |
| | A7 | GRIER et al. | "Regression of Cutaneous Melanosarcoma Following Intralesional Mycobacterium bovis BCG Injection: A Case Report," <i>J. of American Animal Hospital Association</i> , 14:76-81 (1978). | | | | | |
| | A8 | HORN, Thomas | "Intradermal Skin Testing and Treatment with Candida and Mumps Antigens of Verruca Vulgaris", Dialog Abstract No. 121478 dated June 25, 1998. | | | | | |
| | A9 | JOHANSSON et al. | "Dinitrochlorobenzene (DNCB) Treatment of Viral Warts," <i>Acta. Derm Venereol.</i> , 64:529-533 (1984). | | | | | |
| | A10 | JOHNSON et al. | "Warts: A Guide to Their Removal," <i>Consultant</i> 39(1):253-266 (1999). | | | | | |
| | A11 | KLEIN et al. | "Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial," <i>Cancer Immunol Immunother</i> 21:133-140 (1986)* Springer-Verlag | | | | | |
| | A12 | LANDOW, Ken | "Nongenital warts, When is treatment warranted?," <i>Postgraduate Medicine</i> , 99(3):245-249 (1996) | | | | | |
| | A13 | MILLER, et al. | "Human Papillomavirus Infection: Treatment Options for Warts," <i>American Family Physician</i> 53(1):135-143 (1996) | | | | | |
| | A14 | MILLER et al. | <i>Ophthalmic Surg.</i> , Vol. 25, NO. 8, abstract only (1994) | | | | | |
| | A15 | MOND et al. | Abstract of WO 95/13089 (1995) | | | | | |
| | A16 | NAPLES, et al. | "Verruca Vulgaris: Treatment with Natural Interferon Alfa Using a Needleless Injector," <i>Arch Dermatol.</i> , 129:698-700 (1993) | | | | | |
| | A17 | NAYLOR et al. | "Contact Immunotherapy of Resistant Warts," <i>J. Am Acad Dermatol.</i> , 19:679-83 (1988) | | | | | |
| | A18 | NELSON, Nancy | "Cancer Vaccines, Disappointing in the Past, Show Promise," <i>J. of the National Cancer Institute</i> , 88(8):486-488 (1996) | | | | | |
| | A19 | PFISTER et al. | "Role of HPV in Cutaneous Premalignant and Malignant Tumors," <i>Clinics in Dermatology</i> , 15:335-347 (1997) *Elsevier Science Inc., New York, New York. | | | | | |
| | A20 | QUAN et al. | "The role of human papillomavirus in carcinoma," <i>J. Am Acad Dermatol.</i> , 25(4):698-705 (1991) | | | | | |
| | EXAMINER | | | | DATE CONSIDERED | | | |
| |  | | | | 7/13/04 | | | |
| * EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include any copy of this form with next communication to applicant. | | | | | | | | |